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Abstract
Background: Anti-cyclic citrullinated peptide (anti-CCP) antibodies have been of diagnostic value
in Northern European Caucasian patients with rheumatoid arthritis (RA). In these populations,
anti-CCP antibodies are associated with the HLA-DRB1 shared epitope. We assessed the
diagnostic value of anti-CCP antibodies in Greek patients with RA where the HLA shared epitope
was reported in a minority of patients.
Methods: Using an enzyme-linked immunosorbent assay (ELISA) (CCP2) kit, we tested anti-CCP
antibodies in serum samples from 155 Greek patients with RA, 178 patients with other rheumatic
diseases, and 100 blood donors. We also determined rheumatoid factor (RF) and compared it to
anti-CCP antibodies for area under the curve (AUC), sensitivity, specificity and likelihood ratios.
Results: Sensitivity of anti-CCP2 antibodies and RF for RA was 63.2% and 59.1%, and specificity
was 95.0% and 91.2%, respectively. When considered simultaneously, the AUC for anti-CCP
antibodies was 0.90 with 95% CI of 0.87 to 0.93 and the AUC for RF was 0.71 with 95% CI of 0.64
to 0.77. The presence of both antibodies increased specificity to 98.2%. Anti-CCP antibodies were
positive in 34.9% of RF-negative RA patients. Anti-CCP antibodies showed a correlation with the
radiographic joint damage. Anti-CCP-positive RA patients had increased the swollen joint count
and serum CRP concentration compared to anti-CCP-negative RA patients (Mann-Whitney U test,
p = 0.01, and p < 0.001, respectively). However, no correlation was found between anti-CCP
antibodies and DAS28 score (r = 0.13, p = 0.12).
Conclusion: In Greek patients with RA, anti-CCP2 antibodies exhibit a better diagnostic value
than RF and a correlation with radiological joint damage and therefore are useful in everyday
rheumatology practice.
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In recent years it has become clear that early aggressive
treatment in rheumatoid arthritis (RA) reduces joint dam-
age and improves function [1]. To use a potentially toxic
therapy as early as possible we require an accurate diagno-
sis of RA and also information about prognosis in an indi-
vidual patient. Today, the diagnosis of RA depends mainly
on clinical criteria that may take years to fulfill. Apart from
clinical features, autoantibodies contribute to the diagno-
sis of various autoimmune diseases. In RA, rheumatoid
factor (RF) has a fair sensitivity but a low specificity, since
it is present in other rheumatic diseases, in infections, and
in healthy people, especially the elderly [2].
In recent years, the introduction of serum antibodies
against citrulline-containing molecules showed some
promise as diagnostic tools in RA. Citrulline can be
formed by posttranslational enzymatic conversion of
arginine residues, catalyzed by peptidylarginine deimi-
nase enzymes. Citrullinated molecules, the targets of these
antibodies, include filaggrin, keratin, fibrin, and vimentin
[3]. These antibodies are detected by ELISA, where a syn-
thetic cyclic citrullinated peptide (CCP) is used as sub-
strate. After the first generation of anti-CCP test (CCP1)
[4,5] a second generation of anti-CCP test (CCP2) has
been introduced. The sensitivity of anti-CCP2 test in vari-
ous populations ranges between 64% and 74% whereas
the specificity ranges between 90% and 99% [6-11]. A cor-
relation of anti-CCP antibodies with radiographic joint
damage has also been reported [12-15].
In Northern European Caucasian populations, RA has
been found to be associated with the HLA-DRB1 shared
epitope. In these populations, anti-CCP antibody produc-
tion is associated with the HLA-DRB1 shared epitope [14].
However, the shared epitope has been detected in a
minority of Greek patients with RA [16]. Therefore, we
studied the diagnostic and prognostic value of anti-CCP
antibodies in Greek patients with RA.
Methods
Patients
One hundred and fifty five Greek patients with RA
(females 118, males 37; age 60.3 ± 12.8 years [mean ±
SD]) attending the Rheumatology Department of Thes-
saly University Hospital, Larisa, were included in the
study. All patients had RA according to American Rheu-
matism Association 1987 criteria [17]. In these patients
age, sex, disease duration, clinical characteristics, basic
blood and biochemistry tests, and medications were
recorded. Forty four patients were on methotrexate, 37
patients were on leflunomide, 22 patients on hydroxy-
chloroquine, 9 patients on prednizolon, 14 patients on
cyclosporin-A, 4 patients on sulfasalazine, and 25 patients
on anti-TNFα agents plus methotrexate.
One hundred and seventy eight patients with other dis-
eases (females 130, males 48; age 54.9 ± 16.5 years)
served as disease control. All these patients fulfilled the
appropriate criteria for their specific disease. One hundred
blood donors (females 15, males 85; age 39.2 ± 10.4) of
the regional blood transfusion center, served as normal
control. This study was approved by the Ethical Commit-
tee of our Institution.
RA activity
Disease activity was assessed using the DAS28 score [18],
morning stiffness (in minutes), extra-articular manifesta-
tions and C-reactive protein concentration (CRP; mg/dL).
Radiographic assessment
An anteroposterior view X-rays of wrists and hands was
obtained. Two rheumatologists (I.A, A.Z), used a Larsen's
modification [19,20] score to assess radiographic joint
damage in a 0 (no abnormality) to 5 (severe abnormality)
scale, in a blind fashion regarding serology and clinical
status. When needed, the two readers chose the lower
score.
Serology
Serum samples from patients and controls were kept at -
80°C until tested. Anti-CCP antibodies were detected
using the QUANTA lite CCP2 IgG ELISA kit (INOVA diag-
nostics, San Diego CA). The assay was performed accord-
ing to the manufacturer's instructions (cut off value, 20
IU/mL). IgM RF was detected by immuno-nephelometry
(Dade Behring, Marburg, Germany) (cut-off value, 15 IU/
mL). Both assays were performed in blind fashion consid-
ering the final diagnosis and each other's result.
Statistical analysis
Receiver operating characteristic (ROC) curves were
drawn and the area under the curve (AUC) along with cor-
responding confidence intervals (CIs) was calculated.
Diagnostic characteristics were determined by means of
sensitivity, specificity, positive likelihood ratio and nega-
tive likelihood ratio and their CIs thereof with respect to
the gold standard. Correlation between anti-CCP2 anti-
body levels and Larsen score was determined by the Spear-
man's rank correlation test. All reported p-values were
two-tailed and statistical significance was considered at
0.05 level. Statistical analyses were carried out using the
SPSS software.
Results
Frequency of anti-CCP2 antibodies
Demographic, clinical and laboratory features of RA
patients are shown in Table 1. Frequencies of anti-CCP
antibodies and RF in patients and controls are shown in
Table 2. Among patients with RA, 98 patients (63.2%)
had anti-CCP antibodies and 92 patients (59.1%) had RF.Page 2 of 7
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itive and RF-positive, 22 RA patients (14.2%) were anti-
CCP-positive and RF-negative, and 16 RA patients
(10.3%) were anti-CCP-negative and RF-positive. Anti-
CCP and/or RF positivity was present in 75.5% of RA
patients. Among 63 RF-negative RA patients, 22 patients
(34.9%) were anti-CCP-positive. Among 57 anti-CCP-
negative RA patients, 28.1% were RF-positive.
In our non-RA disease control group, 14 patients (7.9%)
had anti-CCP antibodies. Nine of those 14 patients had
very low antibody titres (23.2–27.7 IU/mL). One patient
with systemic lupus erythematosus and a high anti-CCP
antibody titre, had a mother with RA.
In the normal control group, none had anti-CCP antibod-
ies and 3% had RF (Table 2).
Diagnostic value of anti-CCP2 antibody test in rheumatoid 
arthritis
For anti-CCP antibodies and RF, diagnostic value was
described by ROC (receiver operating characteristic)
curve, AUC (Figure 1), sensitivity and specificity, positive
and negative predictive values (Table 3). When sensitivity
and specificity were considered simultaneously, the AUC
for anti-CCP antibodies was 0.90 with 95% CI of 0.87 to
0.93, whereas the AUC for RF was 0.71 with 95% CI of
0.64 to 0.77. Therefore, anti-CCP antibodies exhibited a
better diagnostic value than RF in Greek patients with RA.
When sensitivity and specificity were considered inde-
pendently, sensitivity of anti-CCP antibody test for RA
was 63.2% and specificity was 95.0%, whereas the respec-
tive values for RF were 59.1% and 91.2%.
The presence of either antibody (anti-CCP antibody and/
or RF) increased sensitivity (75.5%), whereas the presence
of both antibodies (anti-CCP antibody and RF) increased
specificity (98.2%).
Anti-CCP2 antibodies and RA activity indices
Disease activity, as defined by the DAS28 score, was low
(DAS28 < 3.2) in 30 RA patients (19.7%), moderate
(DAS28 3.2–5.1) in 68 RA patients (44.7%), and high
(DAS28 > 5.1) in 54 RA patients (35.5%). RA patients
with high DAS28 score had a higher frequency of anti-
CCP antibodies (75.9%) compared to RA patients with
low DAS28 score (31.8%) (p < 0.001). However, no cor-
relation was found between anti-CCP antibodies and dis-
ease activity as defined by the DAS28 score (r = 0.13, p =
0.12). Anti-CCP-positive RA patients had increased swol-
len joint count and serum CRP concentration compared
to anti-CCP-negative RA patients (Mann-Whitney U test,
p = 0.01, and p < 0.001, respectively).
Thirty nine RA patients (72.2%) with high disease activity
were RF(+), compared to 15 RA patients (50.0%) with low
disease activity (not significant). Serum IgM RF levels
showed a correlation with DAS28 score (r = 0.29, p =
0.001). Also, RF(+) RA patients had increased swollen
joint count and serum CRP concentration compared to
RF(-) RA patients (Mann-Whitney U test, p = 0.02, and p
= 0.002, respectively).
Anti-CCP2 antibodies and radiographic joint score
Twelve RA patients had Larsen radiographic score 0-I, 83
patients had score II-III and 36 patients had score IV-V.
Among RA patients with Larsen score IV-V, 28 patients
(77.7%) were anti-CCP-positive and 22 patients (61.0%)
were both anti-CCP-positive and RF-positive. The respec-
tive numbers among RA patients with the Larsen score 0–
1 were 6 (50.0%) and 3 (25.0%). Patients with anti-CCP
antibodies had a trend towards a more severe radio-
graphic joint damage, compared to patients without anti-
CCP antibodies, but this trend did not reach statistical sig-
nificance. However, there was, although a fairly weak, cor-
relation between radiographic joint score and anti-CCP
antibodies (Spearman correlation coefficient, r = 0.27, p =
0.001). When RA patients were divided according to dis-
Table 1: Demographic and clinical characteristics of patients with rheumatoid arthritis
Feature Value(mean ± SD)
Sex (%women) 76%
Age 60.3 (± 12.8) years
Disease duration (n = 153) 11.3 (± 0.8) years
Morning stiffness (n = 137) 32.9 (± 52.6) minutes
Tender joints (n = 153) 8.0 (± 7.0)
Swollen joints (n = 153) 3.0 (± 5.0)
ESR (n = 152) 30.9 (± 22.8) mm/1st hour
CRP (n = 143) 1.8 (± 3.3) mg/dL
DAS28 (n = 152) 4.5 (± 1.6)
Larsen score (n = 131) 2.1 (± 1.1)
Anti-CCP antibodies (n = 155) 81.9 (± 115.4) IU/mL
RF (n = 155) 246.3 (± 508.1) IU/mLPage 3 of 7
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Table 3: Diagnostic performance of anti-CCP2 antibodies and RF in rheumatoid arthritis
Anti-CCP2 R.A. vs non R.A. R.A. vs other diseases R.A. vs blood donors
AUC 0.90 (95% CI: 0.87 – 0.93) 0.87 (95% CI: 0.83 – 0.91) 0.95 (95% CI: 0.92 – 0.97)
Sensitivity* 63.6% (95% CI: 55.8% – 70.8%) 63.6% (95% CI: 55.8% – 70.8%) 63.6% (95% CI: 55.8% – 70.8%)
Specificity* 95.0% (95% CI: 91.7% – 97.0%) 92.1% (95% CI: 87.2% – 95.3%) 100% (95% CI: 96.4% – 100%)
PPV* 87.5% (95% CI: 80.1% – 92.4%) 87.5% (95% CI: 80.1% – 92.4%) 100% (95% CI: 96.2% – 100%)
NPV* 83.8% (95% CI: 80.0% – 87.0%) 74.55% (95% CI: 68.4% – 79.8%) 64.1% (95% CI: 56.3% – 71.2%)
LR +* 12.6 (95% CI: 10.9 – 14.7) 8.1 (95% CI: 6.95 – 9.41) Undefined
LR -* 0.38 (95% CI: 0.37 – 0.40) 0.39 (95% CI: 0.38 – 0.41) 0.36 (95% CI: 0.35 – 0.38)
Diagnostic OR* 33 (95% CI: 17.6 – 61.9) 20.5 (95% CI: 10.8 – 38.8) Undefined
RF R.A. vs non R.A. R.A. vs other diseases R.A. vs blood donors
AUC 0.71 (95% CI: 0.64 – 0.77) 0.719 (95% CI: 0.66 – 0.78) 0.682 (95% CI: 0.61 – 0.76)
Sensitivity* 59.09% (95% CI: 51.2% – 66.5%) 59.09% (95% CI: 51.2% – 66.5%) 59.09% (95% CI: 51.2% – 66.5%)
Specificity* 91.24% (95% CI: 87.3% – 94.0%) 87.93% (95% CI: 82.3% – 92.0%) 97.00% (95% CI: 91.6% – 99.0%)
PPV* 79.13% (95% CI: 70.8% – 85.6%) 81.25% (95% CI: 73.0% – 87.4%) 96.81% (95% CI: 91.0% – 98.9%)
NPV* 79.87% (95% CI: 75.1% – 83.9%) 70.83% (95% CI: 64.5% – 76.5%) 60.62% (95% CI: 52.9% – 67.9%)
LR +* 6.75 (95% CI: 6.13 – 7.43) 4.89 (95% CI: 4.39 – 5.46) 19.70 (95% CI: 10.10 – 38.43)
LR -* 0.45 (95% CI: 0.43 – 0.46) 0.47 (95% CI: 0.45 – 0.48) 0.42 (95% CI: 0.41 – 0.44)
Diagnostic OR* 15.05 (95% CI: 8.88 – 25.51) 10.52 (95% CI: 6.02 – 18.38) 46.70 (95% CI: 14.17 – 154.00)
The AUC for anti-CCP2 antibodies of 0.90 (95% CI, 0.87–0.93) is higher than the AUC for RF of 0.71 (95% CI, 0.64–0.77), with no overlapping of 
the two CIs, and shows that the diagnostic value of anti-CCP2 antibodies is higher than RF in rheumatoid arthritis.
AUC = area under the curve; PPV = positive predictive value; NPV = negative predictive value; LR+ = likelihood ratioof a positive test; LR- = 
likelihood ratioof a negative test OR = odds ratio
Table 2: Anti-CCP2 antibodies and RF in RA and non-RA patients and normal controls.
Disease (n) anti-CCP (%) RF (%)
Rheumatoid arthritis (155) 98 (63.2) 92 (59,1)
Spondyloarthropathies (53) 2 (3.8) 5 (9.4)
Systemic lupus erythematosus (32) 2 (6.2) 6 (18.7)
Sjogren's syndrome (17) 3 (17.6) 3 (17.6)
Osteoarthritis (19) 0 (0.0) 0 (0.0)
Vasculitis (15) 3 (20) 4 (26.7)
Polymyalgia rheumatica (11) 0 (0.0) 0 (0.0)
Crystal arthritis (7) 0 (0.0) 1 (14.3)
Adult onset Still's disease (5) 0 (0.0) 0 (0.0)
Systemic sclerosis (5) 1 (20) 1 (20)
Juvenile idiopathic arthritis (4) 1 (25) 1 (25)
Brucellosis (4) 2 (50) 1 (25)
Others (n = 6) 0 (0.0) 0 (0.0)
Normal controls (100) 0 (0.0) 3 (3.0)
Others = mixed connective tissue disease, familial Mediterranean fever, rheumatic fever, dermatomyositis, anti-phospholipid syndrome.
BMC Musculoskeletal Disorders 2007, 8:37 http://www.biomedcentral.com/1471-2474/8/37ease duration (0–5 years, 5–10 years, more than 10 years),
a correlation of radiographic score with anti-CCP antibod-
ies was found in the group with short disease duration (0–
5 years) (Spearman r = 0.40, p = 0.029). Also, a correlation
was found between RF and radiographic joint score
(Spearman r = 0.33, p= 0.001).
Discussion
The first study on anti-CCP antibodies (CCP1 test)
reported a sensitivity of 68% and specificity of 98% for RA
[4], whereas the same investigators when analyzed
patients from other centers found sensitivity 45–80% and
specificity 96–100% [4]. Other studies utilized CCP2 kits
found sensitivity 64–74% and confirmed the high specif-
icity of the test (90–99%) [6-12]. Anti-CCP antibodies
(CCP1 test) have been used successfully to diagnose per-
sisted arthritis as compared to self-limited arthritis [5], or
to differentiate RA (CCP2 test) from early undifferentiated
arthritis [21]. Our findings of sensitivity of 63.2% and
specificity of 95% for anti-CCP antibodies in RA are in
agreement with these studies. The different frequencies of
anti-CCP antibodies in various RA patient cohorts can be
explained as follows: anti-CCP antibodies are directed
against different epitopes in citrulline-containing mole-
cules and sera from individual patients may contain dif-
ferent subsets of anti-CCP antibodies [22,23]. As observed
with other autoantibodies in autoimmune diseases, the
production of anti-CCP antibodies in RA is influenced by
HLA alleles. Serum anti-CCP antibody levels were higher
in RA patients with the shared HLA-DRB1 (SE) epitope
than in RA patients lacking the SE epitope [14]. Finally,
RA treatment may decrease serum anti-CCP antibody lev-
els. Anti-TNFα treatment has been found to decrease
serum anti-CCP antibody levels [24]. The high specificity
of anti-CCP antibodies is particularly useful in RF-nega-
tive RA patients. In our study, the frequency of anti-CCP
antibodies in RF-negative RA patients was 34.9%, but this
has been reported up to 40% [9].
Nearly a third of anti-CCP-negative RA patients (28.1%)
were RF-positive. The relatively low percentage of RF in
our RA group may be explained by the fact that our RA
patients encompass the full range of RA severity/activity
because of the Health system in Greece: Our Hospital
functions as a primary as well as secondary and tertiary
center. In other countries, where University Hospitals may
only accept referrals from general practitioners, RA
patients may include the more severe cases.
In agreement with another study [9], our study found an
association of anti-CCP antibodies with disease activity as
defined by swollen joint count and increased CRP concen-
tration. Our study is a cross-sectional study and has not
followed RA patients over years to address the significance
of anti-CCP antibodies in joint damage. Nevertheless, our
study demonstrated a correlation between anti-CCP anti-
bodies and radiological joint score in patients with RA.
Similarly, anti-CCP antibodies alone or together with the
HLA-DRB1 shared epitope have been found to be associ-
ated with radiological joint damage [12]. In longitudinal
studies, anti-CCP antibodies alone [15] or together with
the HLA-DRB1 shared epitope [14] have been associated
with faster radiological joint progression. In multiple
regression analysis, anti-CCP1-positivity [25] and anti-
CCP2-positivity [13] have been found to be predictor of
radiological joint outcome. Taken together these findings
suggest that anti-CCP antibodies are useful in predicting a
severe disease course in RA.
The moderate sensitivity and high specificity of anti-CCP
antibodies for RA, along with the appearance of anti-CCP
antibodies before disease onset [26,27], suggest that anti-
CCP antibodies be included in the classification criteria
for RA. Furthermore, the correlation of anti-CCP antibod-
ies with radiographic joint damage in RA [13-15,25] pro-
vides additional aid for clinicians in deciding early
aggressive treatment for a RA patient who is likely to have
a severe disease course.
Conclusion
Anti-CCP2 antibodies had a better diagnostic value than
RF for RA in Greeks. A considerable proportion (34.9%)
of RF-negative RA patients were anti-CCP-positive. Fur-
thermore, RA patients with anti-CCP antibodies were
more likely to have more radiographic joint damage than
patients without anti-CCP antibodies. These results con-
firm results in other populations and suggest that anti-
CCP2 test is useful in everyday rheumatology practice.
Receiver Operating Characteristic (ROC) curve of anti-CCP2 antibodies and rheumatoid factorFigure 1
Receiver Operating Characteristic (ROC) curve of anti-
CCP2 antibodies and rheumatoid factor.Page 5 of 7
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